A Phase 2 interventional study of PF-04965842 200 mg and PF-04965842 100 mg in Atopic Dermatitis, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 15th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 10th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer
Ages 2–5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 150 across the 20 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
58 studies in Dermatitis, Atopic by Pfizer: 11 open now, 13 under way, 4 of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 34th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2020, is one of 13 in phase 2, and was the 23rd registered.
Pfizer’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing abrocitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07848074Fondazione Policlinico Universitario Agostino Gemelli IRCCSAbrocitinib Dose Tapering in Patients With Atopic Dermatitis | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, from their registry updates:
Among Pfizer’s 58 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
B7451037 is a randomized, double-blind, placebo-controlled, parallel-group, Phase 2a study to investigate the mechanism of action of PF-04965842 by correlating efficacy outcomes with changes from baseline in key skin and blood biomarkers in adult participants at least 18 years of age with moderate-to-severe atopic dermatitis. Participants will be screened within 28 days prior to the first dose of study intervention to confirm eligibility. A total of approximately 51 participants will be randomized in a 1:1:1 ratio to receive PF-04965842 200 mg once daily (QD), PF004965842 100 mg QD, or matching placebo QD for 12 weeks. At the end of the 12-week study treatment, qualified participants will have the option to enter the long-term extension study B7451015 (NCT03422822). Participants discontinuing early from this study will undergo a 4-week off-treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-04965842 200 mg
Drug: PF-04965842 100 mg
Drug: Placebo
PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
Placebo administered as two tablets to be taken orally once daily for 12 weeks
Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12
Mean fold-changes from baseline at Week 12 in the biomarkers for general inflammation (Matrix Metallopeptidase \[MMP\]12), hyperplasia (Keratin \[KRT\]16), Th2 immune response (C-C motif chemokine ligand \[CCL\]17, CCL18, CCL26), and Th22 immune response (S100 calcium binding protein A \[S100A\]8, S100A9, S100A12), in lesional (LS) and non-lesional (NL) skin tissues, respectively. Expression levels from RT-PCR are normalized to the housekeeping gene RPLP0 by negatively transforming the Ct values to -dCt.
Time frame: Baseline, Week 12
Fold-Change From Baseline in Cellular (T-cell and Dendritic Cell) Inflammation Markers at Week 12
Mean fold-changes from baseline in immunohistochemistry analysis in lesional skin endpoints at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.
Time frame: Baseline, Week 12
Fold-Change From Baseline in Epidermal Hyperplasia Markers in Skin Biopsies and Skin Thickness at Week 12
Mean fold-changes from baseline in hyperplasia markers in skin biopsies at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.
Time frame: Baseline, Week 12
Fold-Change From Baseline in Blood Biomarkers for Inflammation and Immune Response at Week 12
OLINK Proteomics Microassay was used to analyze biomarkers in serum to assess the effect of abrocitinib on the blood biomarkers. Mean fold-changes at Week 12 from baseline are listed. Baseline is defined as the last observation on or prior to day of first dose (Day 1).
Time frame: Baseline, Week 12
Percent-Change From Baseline in T-cell Lymphocyte Subset Populations at Week 12
Mean percent changes from baseline at Week 12 in T-cell lymphocyte subset populations (CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, B cells) are presented. Baseline is defined as the last observation on or prior to day of first dose (Day 1).
Time frame: Baseline, Week 12
Response Based on at Least 4 Points Improvement in the Severity of Peak Pruritus Numerical Rating Scale (NRS) From Baseline and Changes From Baseline in Immunohistochemistry (IHC) and Gene Expression Biomarkers in Lesional Skin
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder. Spearman correlation coefficient was calculated to assess the relationship between PP-NRS CFB and fold CFB of IHC and gene expression biomarkers.
Time frame: Baseline, Week 12
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline at Week 2, 4, 8 and 12
The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4, 8, and 12
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline Week 2, 4, 8 and 12
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Week 2, 4, 8, and 12
Percentage of Participants With >=4 Points at Baseline and Achieving >=4 Points Improvement From Baseline in Numeric Rating Scale for Severity of Pruritus (PP-NRS) at Weeks 2, 4, 8 and 12
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Week 2, 4, 8, 12
Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline at Week 2, 4, 8 and 12
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline to Week 2, 4, 8 and 12
Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline at Week 2, 4, 8 and 12
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline to Week 2, 4, 8 and 12
Percent Change From Baseline in Percentage Body Surface Area (BSA) at Week 2, 4, 8 and 12
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
Time frame: Baseline and Week 2, 4, 8 and 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
Time frame: Baseline to 16 weeks
Number of Participants With Serious Adverse Events (SAEs)
A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.
Time frame: Baseline to 16 weeks
Number of Participants Who Discontinued From the Study Due to TEAEs
An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
Time frame: Baseline to 16 weeks
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.
Time frame: Baseline to 16 weeks
Change From Baseline in Erythrocytes at Week 2, 4, 8 and 12
Clinical laboratory tests including red blood cell (erythrocytes) were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
Time frame: Baseline and Week 2, 4, 8 and 12
Change From Baseline in Reticulocytes at Week 2, 4, 8 and 12
Clinical laboratory tests including reticulocytes were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
Time frame: Baseline and Week 2, 4, 8 and 12
Change From Baseline in Platelet Counts at Week 2, 4, 8 and 12
Clinical laboratory tests including platelet counts were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
Time frame: Baseline and Week 2, 4, 8 and 12
Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 2, 4, 8 and 12
Clinical laboratory tests including hs-CRP were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
Time frame: Baseline and Week 2, 4, 8 and 12
Change From Baseline in Interleukin 6 at Week 2, 4, 8 and 12
Clinical laboratory tests including interleukin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
Time frame: Baseline and Week 2, 4, 8 and 12
Change From Baseline in Erythropoietin at Week 2, 4, 8 and 12
Clinical laboratory tests including erythropoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
Time frame: Baseline and Week 2, 4, 8 and 12
Change From Baseline in Thrombopoietin at Week 2, 4, 8 and 12
Clinical laboratory tests including thrombopoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
Time frame: Baseline and Week 2, 4, 8 and 12
Change From Baseline in Night Time Itch Scale Score at Week 2, 4, 8 and 12
The severity and frequency of itch (pruritus) during the night due to AD was assessed using the Night Time Itch Scale Score. Participants assessed their worst itching due to AD during their most recent night's sleep on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. The frequency of itch was assessed using a 5-point qualitative scale, with responses including "Never", "Rarely", "Sometimes", "Often" and "Almost Always".
Time frame: Baseline and Week 2, 4, 8 and 12
Plasma PF-04965842 Concentration
Pharmacokinetic (PK) samples were collected at Week 4 and 12 for measurement of plasma concentration of PF-04965842.
Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
Plasma PF-06471658 (M1) Concentration
PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-06471658 (M1).
Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
Plasma PF-07055087 (M2) Concentration
PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-07055087 (M2).
Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
Plasma PF-07054874 (M4) Concentration
PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolites PF-07054874 (M4).
Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
A total of 46 adult participants with moderate-to-severe atopic dermatitis (AD) were randomized to the study and received study intervention, including 16 participants in the abrocitinib (PF-04965842) 100 mg once daily (QD) group, 14 participants in the abrocitinib 200 mg QD group, and 16 participants in the placebo group.
| Milestone | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Started | 16 | 14 | 16 |
| Completed | 14 | 13 | 14 |
| Not completed | 2 | 1 | 2 |
| Withdrew: Adverse event | 2 | 1 | 2 |
Mean fold-changes from baseline at Week 12 in the biomarkers for general inflammation (Matrix Metallopeptidase \[MMP\]12), hyperplasia (Keratin \[KRT\]16), Th2 immune response (C-C motif chemokine ligand \[CCL\]17, CCL18, CCL26), and Th22 immune response (S100 calcium binding protein A \[S100A\]8, S100A9, S100A12), in lesional (LS) and non-lesional (NL) skin tissues, respectively. Expression levels from RT-PCR are normalized to the housekeeping gene RPLP0 by negatively transforming the Ct values to -dCt.
| Fold change | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| CCL17 (LS) | -5.896 ± 16.0867 | -15.604 ± 38.5469 | -0.729 ± 4.0821 |
| CCL17 (NL) | -0.506 ± 7.5268 | -3.150 ± 2.6554 | -3.354 ± 7.6800 |
| CCL18 (LS) | -11.600 ± 18.9748 | -24.558 ± 46.2466 | -1.096 ± 3.6800 |
| CCL18 (NL) | -18.307 ± 24.0808 | -12.328 ± 13.3680 | -0.761 ± 2.8516 |
| CCL26 (LS) | -3.886 ± 9.6426 | -0.464 ± 5.2150 | -0.205 ± 1.7928 |
| CCL26 (NL) | -3.619 ± 2.1674 | -4.369 ± 8.0621 | 0.026 ± 2.0613 |
| KRT16 (LS) | -24.604 ± 47.3896 | -53.285 ± 70.6935 | -1.898 ± 19.4730 |
| KRT16 (NL) | -3.179 ± 6.2518 | -2.947 ± 1.4188 | -2.674 ± 7.2836 |
| MMP-12 (LS) | -44.200 ± 123.0708 | -306.161 ± 503.8312 | -0.184 ± 3.0962 |
| MMP-12 (NL) | -20.822 ± 31.5640 | -27.523 ± 16.5608 | -1.897 ± 3.6968 |
| S100A12 (LS) | -13.931 ± 23.9740 | -1322.88 ± 4594.187 | 5.994 ± 57.0002 |
| S100A12 (NL) | 4.052 ± 0.4124 | -4.300 ± 4.2217 | -14.200 ± 21.2222 |
| S100A8 (LS) | -76.158 ± 181.1015 | -312.430 ± 395.0796 | 1.213 ± 31.0236 |
| S100A8 (NL) | -3.797 ± 3.9226 | -14.249 ± 13.2540 | -8.394 ± 10.7181 |
| S100A9 (LS) | -52.132 ± 113.0256 | -304.023 ± 376.0106 | -2.136 ± 17.2326 |
| S100A9 (NL) | -2.781 ± 5.6012 | -34.776 ± 42.4019 | -7.368 ± 10.0856 |
Mean fold-changes from baseline in immunohistochemistry analysis in lesional skin endpoints at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.
| Fold change | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| CD11C | -1.622 (-2.404 to -1.094) | -2.460 (-3.719 to -1.627) | -1.326 (-1.968 to 1.118) |
| CD3 | -1.952 (-2.979 to -1.279) | -2.371 (-3.696 to -1.521) | -1.054 (-1.610 to 1.450) |
| Fc Epsilon R1 | -1.610 (-2.276 to -1.140) | -2.088 (-3.003 to -1.453) | 1.092 (-1.295 to 1.545) |
| Macrophage mannose receptor 1 | -1.249 (-1.538 to -1.015) | -1.835 (-2.282 to -1.476) | -1.155 (-1.422 to 1.066) |
Mean fold-changes from baseline in hyperplasia markers in skin biopsies at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.
| Fold change | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Ki-67 | -1.638 (-2.859 to 1.066) | -1.911 (-3.432 to -1.064) | -1.153 (-2.016 to 1.516) |
| Thickness | -1.310 (-1.735 to 1.010) | -1.508 (-2.024 to -1.123) | -1.185 (-1.570 to 1.118) |
OLINK Proteomics Microassay was used to analyze biomarkers in serum to assess the effect of abrocitinib on the blood biomarkers. Mean fold-changes at Week 12 from baseline are listed. Baseline is defined as the last observation on or prior to day of first dose (Day 1).
| Fold change | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| C-C motif chemokine ligand 23 (CCL23) | -0.247 ± 0.3367 | -0.519 ± 0.3958 | -0.245 ± 0.4302 |
| C-C motif chemokine ligand 17 (CCL17) | -0.619 ± 0.8281 | -0.880 ± 1.0630 | 0.108 ± 0.8299 |
| Selectin E (SELE) | -0.520 ± 0.6198 | -0.717 ± 0.6172 | -0.170 ± 0.3571 |
| Integrin subunit beta 2 (ITGB2) | -0.280 ± 0.3067 | -0.574 ± 0.2649 | 0.058 ± 0.1877 |
| Platelet-derived growth factor (PDGF) subunit B | -0.057 ± 0.2185 | -0.182 ± 0.3561 | 0.085 ± 0.2916 |
| PDGF subunit A | -0.360 ± 0.3354 | -0.590 ± 0.3884 | -0.039 ± 0.1802 |
| Linker for activation of T cells (LAT) | -0.127 ± 0.4281 | -0.322 ± 0.3329 | -0.169 ± 0.3493 |
| C-C motif chemokine ligand 24 (CCL24) | -0.283 ± 0.5321 | -0.342 ± 0.2439 | -0.191 ± 0.2425 |
| Lipoprotein lipase (LPL) | -0.037 ± 0.5906 | 0.281 ± 0.7465 | -0.224 ± 0.7340 |
| Interferon (IFN)-gamma | 0.264 ± 1.2382 | 0.903 ± 1.9580 | 0.763 ± 1.1019 |
| Interleukin 2 receptor subunit alpha (IL2-RA) | -0.852 ± 0.6237 | -0.921 ± 0.4530 | -0.219 ± 0.3161 |
| Interleukin (IL)-1 alpha | 0.118 ± 0.4804 | -0.114 ± 0.2527 | 0.046 ± 0.3275 |
| C-C motif chemokine ligand 25 (CCL25) | 0.229 ± 0.3299 | 0.324 ± 0.4351 | 0.149 ± 0.2235 |
| C-C motif chemokine ligand 28 (CCL28) | 0.014 ± 0.2452 | 0.108 ± 0.2932 | 0.011 ± 0.2962 |
| C-C motif chemokine ligand 20 (CCL20) | -0.465 ± 1.1905 | 0.111 ± 0.8023 | -0.333 ± 0.6612 |
| C-C motif chemokine ligand 19 (CCL19) | -0.653 ± 0.6620 | -1.217 ± 0.9084 | -0.012 ± 0.5347 |
| C-C motif chemokine ligand 16 (CCL16) | -0.258 ± 0.2716 | -0.313 ± 0.1866 | -0.103 ± 0.2040 |
| C-C motif chemokine ligand 11 (CCL11) | 0.030 ± 0.2617 | 0.109 ± 0.2891 | 0.060 ± 0.2005 |
| MMP-12 | -0.554 ± 0.9534 | -0.756 ± 0.6576 | -0.631 ± 0.9298 |
| Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) | -0.437 ± 0.3796 | -0.608 ± 0.2665 | -0.136 ± 0.2562 |
| Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) | -0.143 ± 0.3348 | -0.048 ± 0.3744 | -0.078 ± 0.4294 |
| Matrix metalloproteinase-1 (MMP-1) | -0.118 ± 0.1546 | 0.004 ± 0.2445 | -0.002 ± 0.1309 |
| Interleukin 20 receptor subunit alpha (IL-20RA) | 0.089 ± 0.2394 | -0.111 ± 0.2573 | -0.040 ± 0.2018 |
| IL-18 | -0.488 ± 0.4737 | -0.578 ± 0.3460 | -0.182 ± 0.4037 |
| IL-16 | -0.512 ± 0.5606 | -0.697 ± 0.5642 | -0.222 ± 0.5656 |
| IL-12 | -0.548 ± 0.5020 | -0.628 ± 0.3935 | -0.141 ± 0.3341 |
| IL-12B | -0.560 ± 0.4540 | -0.637 ± 0.3808 | -0.059 ± 0.3230 |
| IL-17C | -0.250 ± 1.2265 | 0.136 ± 0.5533 | -0.784 ± 1.0808 |
| IL-7 | -0.082 ± 0.4541 | -0.425 ± 0.5173 | -0.020 ± 0.5239 |
| IL-27 | -0.099 ± 0.1617 | -0.177 ± 0.2611 | -0.073 ± 0.2250 |
| IL-13 | -0.230 ± 0.4810 | -0.490 ± 0.6399 | -0.213 ± 0.6765 |
| IL-17D | 0.057 ± 0.3222 | -0.222 ± 0.2921 | -0.105 ± 0.2420 |
| IL-20 | -0.155 ± 0.2843 | -0.171 ± 0.2315 | -0.137 ± 0.3877 |
| IL-4 | -0.130 ± 0.6704 | -0.308 ± 0.5324 | -0.128 ± 0.3287 |
| IL-4RA | -0.075 ± 0.2436 | -0.619 ± 0.7577 | -0.340 ± 0.5764 |
| IL-2 | 0.005 ± 0.1927 | -0.069 ± 0.2345 | 0.050 ± 0.3024 |
| IL-8 | 0.080 ± 0.8463 | 0.090 ± 0.8062 | 0.152 ± 0.9180 |
| IL-5 | 0.049 ± 0.2578 | -0.164 ± 0.3214 | -0.020 ± 0.3306 |
| IL-6 | -0.086 ± 0.9560 | 0.150 ± 1.4005 | -0.228 ± 1.1986 |
| IL-10 | -0.180 ± 0.4616 | -0.087 ± 0.4255 | -0.182 ± 0.6735 |
| IL-33 | 0.022 ± 0.2275 | -0.116 ± 0.2353 | -0.138 ± 0.2815 |
| Cluster of differentiation (CD) 5 | -0.373 ± 0.2546 | -0.405 ± 0.1488 | -0.064 ± 0.1640 |
| CD4 | -0.252 ± 0.3139 | -0.406 ± 0.2184 | -0.159 ± 0.3220 |
| CD40 | -0.049 ± 0.1755 | -0.065 ± 0.3002 | 0.039 ± 0.2065 |
| Peptidase Inhibitor 3 (PI3) | -0.463 ± 0.6634 | -0.332 ± 0.6725 | -0.583 ± 0.8686 |
| Tumor necrosis factor (TNF) | -0.328 ± 0.3560 | -0.227 ± 0.6622 | 0.036 ± 0.9515 |
| C-X-C motif chemokine ligand 5 (CXCL5) | -0.208 ± 0.2889 | -0.364 ± 0.4082 | 0.068 ± 0.4028 |
| X-C motif chemokine ligand 1 (XCL1) | -0.540 ± 0.4209 | -0.897 ± 0.4253 | -0.051 ± 0.3028 |
| Thymic stromal lymphopoietin (TSLP) | -0.100 ± 0.4871 | -0.047 ± 0.5610 | 0.019 ± 0.4495 |
| CXCL10 | -0.268 ± 0.9825 | -0.549 ± 0.9508 | 0.363 ± 0.4782 |
| CXCL11 | -0.399 ± 0.6089 | -0.695 ± 0.7402 | 0.210 ± 0.4335 |
| CXCL9 | -0.161 ± 0.6273 | -0.406 ± 0.9061 | 0.159 ± 0.5395 |
| CXCL1 | -0.218 ± 0.3795 | -0.375 ± 0.3356 | -0.062 ± 0.3892 |
| CXCL16 | 0.031 ± 0.2575 | -0.033 ± 0.2503 | -0.011 ± 0.1563 |
| Transforming growth factor (TGF)-beta-1 | -0.199 ± 0.2853 | -0.465 ± 0.2884 | -0.077 ± 0.2521 |
| CCL3 | -0.168 ± 0.4852 | -0.171 ± 0.5503 | 0.247 ± 0.7508 |
| CX3CL1 | 0.346 ± 0.4784 | 0.458 ± 0.4269 | 0.012 ± 0.2771 |
| CCL4 | -0.187 ± 0.3558 | -0.085 ± 0.5211 | 0.204 ± 0.4349 |
| Membrane cofactor protein (MCP)-4 | -0.627 ± 0.7270 | -0.860 ± 0.6659 | -0.116 ± 0.6018 |
| MCP-3 | -0.418 ± 0.8078 | -0.676 ± 0.5462 | -0.229 ± 0.7573 |
| MCP-1 | 0.053 ± 0.4337 | 0.108 ± 0.3722 | -0.081 ± 0.3836 |
| MCP-2 | -0.204 ± 0.2714 | -0.552 ± 0.3286 | -0.007 ± 0.2398 |
| IL-1ra | -0.295 ± 0.4298 | -0.234 ± 0.6936 | -0.128 ± 0.6599 |
| IL-6RA | -0.162 ± 0.2087 | -0.274 ± 0.1833 | -0.022 ± 0.1817 |
| Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) | -0.062 ± 0.2606 | -0.283 ± 0.2998 | 0.086 ± 0.2172 |
| TNF-related weak inducer of apoptosis (TWEAK) | -0.057 ± 0.2239 | -0.157 ± 0.1705 | 0.099 ± 0.1471 |
| EN-RAGE | -0.175 ± 0.6414 | -0.383 ± 0.9149 | 0.175 ± 0.7755 |
| P-selectin glycoprotein ligand-1 (PSGL-1) | -0.025 ± 0.2592 | -0.087 ± 0.1646 | -0.012 ± 0.1856 |
Mean percent changes from baseline at Week 12 in T-cell lymphocyte subset populations (CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, B cells) are presented. Baseline is defined as the last observation on or prior to day of first dose (Day 1).
| Percent change | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| T-cells TBNK Screening (%) | -0.2 ± 5.25 | 3.6 ± 6.65 | 1.7 ± 3.69 |
| T-cells TBNK Screening (absolute) | -14.5 ± 19.50 | 14.2 ± 43.43 | 1.5 ± 29.10 |
| T lymphocytes CD3+CD4 (%) | 1.4 ± 7.18 | 6.7 ± 11.73 | 5.6 ± 7.96 |
| T lymphocytes CD3+CD4 (absolute) | -13.2 ± 20.06 | 17.1 ± 41.66 | 5.2 ± 29.79 |
| T lymphocytes CD3+CD8 (%) | -0.7 ± 12.22 | 3.2 ± 10.59 | -1.6 ± 8.75 |
| T lymphocytes CD3+CD8 (absolute) | -15.1 ± 22.19 | 16.2 ± 54.75 | -1.1 ± 33.17 |
| B-cells TBNK Screening (%) | 35.5 ± 41.18 | 42.4 ± 37.49 | 7.8 ± 23.69 |
| B-cells TBNK Screening (absolute) | 18.3 ± 52.71 | 55.0 ± 59.81 | 7.7 ± 39.19 |
| NK Cells TBNK Screening (%) | -27.3 ± 40.12 | -55.9 ± 24.04 | -15.2 ± 28.64 |
| NK Cells TBNK Screening (absolute) | -40.0 ± 29.41 | -53.2 ± 26.96 | -17.9 ± 26.81 |
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder. Spearman correlation coefficient was calculated to assess the relationship between PP-NRS CFB and fold CFB of IHC and gene expression biomarkers.
| Spearman correlation coefficient | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| CD11C | 0.242 | 0.484 | 0.439 |
| FC Epsilon R1 | 0.474 | 0.464 | 0.238 |
| CD3 | 0.438 | 0.408 | 0.151 |
| Macrophage mannose receptor 1 | 0.396 | 0.162 | -0.134 |
| S100A9 | 0.390 | 0.529 | 0.334 |
| S100A8 | 0.365 | 0.510 | 0.413 |
| KRT16 | 0.313 | 0.486 | 0.522 |
| S100A12 | 0.238 | 0.454 | 0.460 |
| CCL18 | 0.395 | 0.410 | 0.365 |
The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | 0 (0.0 to 0.0) | 7.7 (0.0 to 22.2) | 0 (0.0 to 0.0) |
| Week 4 | 26.7 (4.3 to 49.0) | 35.7 (10.6 to 60.8) | 0 (0.0 to 0.0) |
| Week 8 | 26.7 (4.3 to 49.0) | 64.3 (39.2 to 89.4) | 0 (0.0 to 0.0) |
| Week 12 | 25.0 (3.8 to 46.2) | 57.1 (31.2 to 83.1) | 0 (0.0 to 0.0) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | 6.3 (0.0 to 18.1) | 38.5 (12.0 to 64.9) | 0 (0.0 to 0.0) |
| Week 4 | 46.7 (21.4 to 71.9) | 50.0 (23.8 to 76.2) | 0 (0.0 to 0.0) |
| Week 8 | 46.7 (21.4 to 71.9) | 78.6 (57.1 to 100.0) | 0 (0.0 to 0.0) |
| Week 12 | 43.8 (19.4 to 68.1) | 78.6 (57.1 to 100.0) | 0 (0.0 to 0.0) |
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | 25.0 (3.8 to 46.2) | 57.1 (31.2 to 83.1) | 6.3 (0.0 to 18.1) |
| Week 4 | 53.3 (28.1 to 78.6) | 64.3 (39.2 to 89.4) | 0 (0.0 to 0.0) |
| Week 8 | 46.7 (21.4 to 71.9) | 64.3 (39.2 to 89.4) | 13.3 (0.0 to 30.5) |
| Week 12 | 35.7 (10.6 to 60.8) | 64.3 (39.2 to 89.4) | 6.3 (0.0 to 18.1) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) |
| Week 4 | 20.0 (0.0 to 40.2) | 28.6 (4.9 to 52.2) | 0 (0.0 to 0.0) |
| Week 8 | 20.0 (0.0 to 40.2) | 57.1 (31.2 to 83.1) | 0 (0.0 to 0.0) |
| Week 12 | 37.5 (13.8 to 61.2) | 50.0 (23.8 to 76.2) | 0 (0.0 to 0.0) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | 37.5 (13.8 to 61.2) | 61.5 (35.1 to 88.0) | 12.5 (0.0 to 28.7) |
| Week 4 | 66.7 (42.8 to 90.5) | 100.0 (100.0 to 100.0) | 6.7 (0.0 to 19.3) |
| Week 8 | 53.3 (28.1 to 78.6) | 100.0 (100.0 to 100.0) | 6.7 (0.0 to 19.3) |
| Week 12 | 68.8 (46.0 to 91.5) | 92.9 (79.4 to 100.0) | 18.8 (0.0 to 37.9) |
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
| Percent change | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | -9.6 ± 12.06 | -17.3 ± 13.78 | 4.0 ± 17.25 |
| Week 4 | -18.7 ± 15.70 | -23.8 ± 14.19 | 2.1 ± 18.35 |
| Week 8 | -18.7 ± 20.96 | -28.3 ± 16.84 | 0.2 ± 21.59 |
| Week 12 | -22.0 ± 19.03 | -28.3 ± 16.95 | -0.2 ± 23.20 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
| Participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| All-causality TEAEs | 10 | 7 | 8 |
| Treatment-related TEAEs | 6 | 5 | 3 |
A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.
| Participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| All-causality SAEs | 0 | 0 | 1 |
| Treatment-related SAEs | 0 | 0 | 1 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
| Participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| All-causality TEAEs | 2 | 1 | 2 |
| Treatment-related TEAEs | 2 | 1 | 1 |
Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.
| Participants | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Hemoglobin (g/dL) <0.8*LLN | 1 | 0 | 0 |
| Hematocrit (%) < 0.8*LLN | 1 | 0 | 0 |
| Erythrocytes (10^6/mm3) < 0.8*LLN | 1 | 0 | 0 |
| Reticulocytes (10^3/mm3) < 0.5*LLN | 1 | 0 | 0 |
| Platelets (10^3/mm3) < 0.5*LLN | 1 | 0 | 0 |
| Reticulocytes/Erythrocytes (%) > 1.5*ULN | 1 | 0 | 0 |
| Leukocytes (10^3/mm3) < 0.6*LLN | 1 | 0 | 0 |
| Lymphocytes (10^3/mm3) < 0.8*LLN | 2 | 0 | 0 |
| Lymphocytes/Leukocytes (%) < 0.8*LLN | 3 | 0 | 1 |
| Lymphocytes/Leukocytes (%) > 1.2*ULN | 0 | 1 | 0 |
| Neutrophils (10^3/mm3) < 0.8*LLN | 1 | 3 | 0 |
| Neutrophils/Leukocytes (%) < 0.8*LLN | 0 | 2 | 2 |
| Basophils/Leukocytes (%) > 1.2*ULN | 1 | 1 | 2 |
| Eosinophils (10^3/mm3) > 1.2*ULN | 5 | 2 | 10 |
| Eosinophils/Leukocytes (%) > 1.2*ULN | 6 | 2 | 10 |
| Monocytes (10^3/mm3) > 1.2x ULN | 0 | 1 | 0 |
| Monocytes/Leukocytes (%) > 1.2*ULN | 1 | 3 | 0 |
| Prothrombin Time (sec) > 1.1*ULN | 1 | 0 | 0 |
| Bilirubin (mg/dL) > 1.5*ULN | 0 | 1 | 0 |
| Indirect Bilirubin (mg/dL) > 1.5*ULN | 0 | 1 | 0 |
| Aspartate Aminotransferase (U/L) > 3.0*ULN | 0 | 1 | 0 |
| Alanine Aminotransferase (U/L) > 3.0*ULN | 0 | 0 | 1 |
| Gamma Glutamyl Transferase (U/L) > 3.0*ULN | 1 | 0 | 0 |
| Lactate Dehydrogenase (U/L) > 3.0*ULN | 0 | 1 | 0 |
| Creatinine (mg/dL) > 1.3*ULN | 1 | 0 | 0 |
| Urate (mg/dL) > 1.2*ULN | 1 | 1 | 0 |
| Potassium (mEq/L) < 0.9*LLN | 1 | 1 | 0 |
| Bicarbonate (mEq/L) > 1.1*ULN | 0 | 1 | 0 |
| Creatine Kinase (U/L) > 2.0*ULN | 1 | 3 | 2 |
| Cholesterol (mg/dL) > 1.3*ULN | 0 | 0 | 1 |
| Ketones ≥ 1 | 0 | 2 | 0 |
| URINE Protein ≥ 1 | 0 | 1 | 1 |
| URINE Hemoglobin ≥ 1 | 2 | 2 | 0 |
| Leukocyte Esterase ≥ 1 | 5 | 3 | 1 |
| URINE Leukocytes (Scalar) ≥ 20 | 2 | 0 | 0 |
| Hyaline Casts (/LPF) > 1 | 2 | 1 | — |
Clinical laboratory tests including red blood cell (erythrocytes) were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
| 10^6 cells/mm^3 | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | -0.12 ± 0.212 | -0.21 ± 0.305 | -0.10 ± 0.242 |
| Week 4 | -0.16 ± 0.279 | -0.19 ± 0.266 | -0.11 ± 0.274 |
| Week 8 | -0.21 ± 0.301 | -0.35 ± 0.424 | -0.02 ± 0.246 |
| Week 12 | -0.35 ± 0.376 | -0.47 ± 0.434 | 0.07 ± 0.183 |
Clinical laboratory tests including reticulocytes were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
| 10^3 cells/mm^3 | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | -15.43 ± 23.177 | -25.14 ± 28.057 | 5.33 ± 12.199 |
| Week 4 | -11.64 ± 27.845 | -20.86 ± 28.710 | 1.86 ± 16.209 |
| Week 8 | -9.31 ± 15.997 | -13.23 ± 18.682 | 0.07 ± 15.345 |
| Week 12 | -5.07 ± 16.615 | -7.64 ± 28.169 | 4.33 ± 20.318 |
Clinical laboratory tests including platelet counts were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
| 10^3 cells/mm^3 | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | -72.86 ± 93.413 | -53.23 ± 28.176 | 12.87 ± 51.582 |
| Week 4 | -89.79 ± 123.180 | -93.29 ± 36.123 | 11.79 ± 33.025 |
| Week 8 | -68.15 ± 102.846 | -71.38 ± 44.925 | 5.79 ± 28.917 |
| Week 12 | -59.00 ± 104.408 | -65.79 ± 42.600 | 5.47 ± 34.620 |
Clinical laboratory tests including hs-CRP were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
| milligrams per deciliter | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | -0.26 ± 0.431 | -0.07 ± 0.147 | -0.13 ± 1.538 |
| Week 4 | -0.24 ± 0.376 | -0.09 ± 0.217 | -0.43 ± 1.283 |
| Week 8 | -0.19 ± 0.287 | 0.03 ± 0.253 | -0.42 ± 1.182 |
| Week 12 | -0.15 ± 0.368 | 0.01 ± 0.254 | -0.40 ± 1.114 |
Clinical laboratory tests including interleukin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
| picograms per milliliter | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | -0.02 ± 2.732 | -0.11 ± 7.021 | -0.44 ± 2.797 |
| Week 4 | 0.16 ± 2.533 | -0.85 ± 5.045 | -1.83 ± 6.034 |
| Week 8 | 0.19 ± 1.391 | 0.15 ± 5.728 | -3.52 ± 8.228 |
| Week 12 | -0.23 ± 2.712 | -0.19 ± 5.305 | -2.59 ± 6.339 |
Clinical laboratory tests including erythropoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
| milliunits per milliliter | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | 5.38 ± 7.042 | 15.78 ± 29.596 | 0.59 ± 7.412 |
| Week 4 | 5.30 ± 6.286 | 14.60 ± 30.438 | 0.35 ± 8.294 |
| Week 8 | 7.84 ± 8.305 | 34.12 ± 58.113 | -1.99 ± 8.101 |
| Week 12 | 7.86 ± 15.831 | 54.08 ± 136.613 | -3.11 ± 6.391 |
Clinical laboratory tests including thrombopoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.
| Picograms per milliliter (pg/mL) | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Week 2 | 38.33 ± 61.921 | 47.64 ± 38.472 | 13.29 ± 31.665 |
| Week 4 | 107.93 ± 274.324 | 103.07 ± 136.964 | -9.36 ± 31.030 |
| Week 8 | 26.93 ± 49.260 | 76.54 ± 116.433 | 4.57 ± 33.073 |
| Week 12 | 30.93 ± 53.723 | 89.57 ± 201.700 | -7.00 ± 30.166 |
The severity and frequency of itch (pruritus) during the night due to AD was assessed using the Night Time Itch Scale Score. Participants assessed their worst itching due to AD during their most recent night's sleep on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. The frequency of itch was assessed using a 5-point qualitative scale, with responses including "Never", "Rarely", "Sometimes", "Often" and "Almost Always".
| Units on a scale | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| NRS01-Severity of Night Time Itch Week 2 | -2.4 ± 2.16 | -4.6 ± 2.79 | -0.3 ± 1.83 |
| NRS01-Severity of Night Time Itch Week 4 | -4.4 ± 3.38 | -4.9 ± 3.52 | -1.1 ± 2.53 |
| NRS01-Severity of Night Time Itch Week 8 | -3.5 ± 4.14 | -5.5 ± 3.52 | -0.8 ± 2.85 |
| NRS01-Severity of Night Time Itch Week 12 | -3.4 ± 3.80 | -4.8 ± 3.77 | -1.1 ± 2.46 |
| NRS01-Frequency of Night Time Itch Week 2 | -0.8 ± 0.91 | -2.1 ± 1.14 | -0.2 ± 1.08 |
| NRS01-Frequency of Night Time Itch Week 4 | -1.8 ± 1.08 | -2.5 ± 1.09 | -0.6 ± 1.12 |
| NRS01-Frequency of Night Time Itch Week 8 | -1.4 ± 1.35 | -2.7 ± 1.14 | -0.6 ± 1.39 |
| NRS01-Frequency of Night Time Itch Week 12 | -1.2 ± 1.21 | -2.5 ± 1.45 | -0.4 ± 1.22 |
Pharmacokinetic (PK) samples were collected at Week 4 and 12 for measurement of plasma concentration of PF-04965842.
| nanogram per milliliter (ng/mL) | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD |
|---|---|---|
| Day 29 Hour 0 | 14.77 ± 29.293 | 135.7 ± 272.53 |
| Day 29 30 minute | 266.6 ± 381.11 | 802.7 ± 1128.2 |
| Day 85 30 minute | 617.6 ± 588.85 | 792.2 ± 1013.9 |
| Day 85 Hour 4 | 433.0 ± 255.44 | 1147 ± 580.56 |
PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-06471658 (M1).
| ng/mL | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD |
|---|---|---|
| Day 29 Hour 0 | 2.588 ± 3.4071 | 23.13 ± 47.649 |
| Day 29 30 minute | 65.82 ± 137.66 | 95.54 ± 108.21 |
| Day 85 30 minute | 92.51 ± 80.717 | 65.03 ± 51.765 |
| Day 85 Hour 4 | 82.84 ± 70.532 | 104.9 ± 80.782 |
PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-07055087 (M2).
| ng/mL | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD |
|---|---|---|
| Day 29 Hour 0 | 9.933 ± 22.629 | 23.86 ± 40.798 |
| Day 29 30 minute | 42.89 ± 66.789 | 73.84 ± 75.245 |
| Day 85 30 minute | 77.56 ± 63.483 | 70.58 ± 67.136 |
| Day 85 Hour 4 | 100.0 ± 46.321 | 132.9 ± 69.048 |
PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolites PF-07054874 (M4).
| ng/mL | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD |
|---|---|---|
| Day 29 Hour 0 | 16.10 ± 33.537 | 48.43 ± 83.563 |
| Day 29 30 minute | 63.76 ± 80.663 | 153.4 ± 163.23 |
| Day 85 30 minute | 149.9 ± 126.33 | 158.2 ± 174.55 |
| Day 85 Hour 4 | 170.4 ± 68.419 | 268.2 ± 173.11 |
Collected over Baseline up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abrocitinib 100 mg QD | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Abrocitinib 200 mg QD | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| Placebo | 0/16 (0%) | 1/16 (6.3%) | 7/16 (43.8%) |
| Event | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| Eczema herpeticumInfections and infestations | 0/16 | 0/14 | 1/16 |
| Periorbital cellulitisInfections and infestations | 0/16 | 0/14 | 1/16 |
| SepsisInfections and infestations | 0/16 | 0/14 | 1/16 |
| Event | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 3/16 | 4/14 | 1/16 |
| HeadacheNervous system disorders | 1/16 | 2/14 | 0/16 |
| DizzinessNervous system disorders | 2/16 | 1/14 | 0/16 |
| Abdominal distensionGastrointestinal disorders | 0/16 | 1/14 | 0/16 |
| HaemorrhoidsGastrointestinal disorders | 0/16 | 1/14 | 0/16 |
| Rectal haemorrhageGastrointestinal disorders | 0/16 | 1/14 | 0/16 |
| FolliculitisInfections and infestations | 0/16 | 1/14 | 0/16 |
| Herpes simplexInfections and infestations | 0/16 | 1/14 | 0/16 |
| Aspartate aminotransferase increasedInvestigations | 0/16 | 1/14 | 0/16 |
| Blood creatine phosphokinase increasedInvestigations | 0/16 | 1/14 | 0/16 |
Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.
| Age, Continuous(Years) | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo | Total |
|---|---|---|---|---|
| Mean | 46.6 ± 19.41 | 41.4 ± 16.72 | 38.9 ± 15.64 | 42.4 ± 17.28 |
| Sex: Female, Male(Participants) | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo | Total |
|---|---|---|---|---|
| Female | 11 | 7 | 3 | 21 |
| Male | 5 | 7 | 13 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 3 | 8 |
| Not Hispanic or Latino | 13 | 12 | 11 | 36 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Abrocitinib 100 mg QD | Abrocitinib 200 mg QD | Placebo | Total |
|---|---|---|---|---|
| White | 10 | 5 | 11 | 26 |
| Black or African American | 4 | 1 | 2 | 7 |
| Asian | 1 | 6 | 2 | 9 |
| Multiracial | 0 | 1 | 1 | 2 |
| Not reported | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2020 to primary completion in Nov 2021, 16 months.
Results were first posted in Feb 2023, 1 year 2 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib